Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AURORA 2: Aurinia Renal Response in Lupus With Voclosporin

Next Previous
Search
Trial Profile

AURORA 2: Aurinia Renal Response in Lupus With Voclosporin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voclosporin (Primary) ; Mycophenolate mofetil; Steroids
  • Indications Lupus nephritis
  • Focus Adverse reactions; Registrational
  • Acronyms AURORA 2
  • Sponsors Aurinia Pharmaceuticals

Most Recent Events

  • 15 Nov 2024 According to Aurinia Pharmaceuticals Inc. media release, company will present data from this study at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., Sunday, November 17, 2024.
  • 11 Oct 2024 According to Aurinia Pharmaceuticals Inc. media release, company will present new data highlighting the important role that LUPKYNIS in Treating Lupus Nephritis will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 taking place in San Diego, CA October 23-27.
  • 24 Sep 2024 According to an Aurinia Pharmaceuticals media release, the company announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN) based on data from the AURORA Clinical Program

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top